Now, the descendant of that molecule — Gilead Sciences’ remdesivir — is being rushed to patients with infections from the novel coronavirus in hopes that it can reduce the intensity and duration of Covid-19 and ease the burden of the pandemic on health systems.
Remdesivir is now in the spotlight as scientists and governments scramble to hasten patients’ recovery and ease the pandemic’s burden on health systems.